GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Emergent BioSolutions Inc (LTS:0IGA) » Definitions » Cyclically Adjusted PB Ratio

Emergent BioSolutions (LTS:0IGA) Cyclically Adjusted PB Ratio : 0.16 (As of Jun. 04, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Emergent BioSolutions Cyclically Adjusted PB Ratio?

As of today (2024-06-04), Emergent BioSolutions's current share price is $6.142. Emergent BioSolutions's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was $37.75. Emergent BioSolutions's Cyclically Adjusted PB Ratio for today is 0.16.

The historical rank and industry rank for Emergent BioSolutions's Cyclically Adjusted PB Ratio or its related term are showing as below:

LTS:0IGA' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.07   Med: 2.9   Max: 8.34
Current: 0.26

During the past years, Emergent BioSolutions's highest Cyclically Adjusted PB Ratio was 8.34. The lowest was 0.07. And the median was 2.90.

LTS:0IGA's Cyclically Adjusted PB Ratio is ranked better than
91.57% of 724 companies
in the Drug Manufacturers industry
Industry Median: 1.875 vs LTS:0IGA: 0.26

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Emergent BioSolutions's adjusted book value per share data for the three months ended in Mar. 2024 was $12.670. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $37.75 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Emergent BioSolutions Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Emergent BioSolutions's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Emergent BioSolutions Cyclically Adjusted PB Ratio Chart

Emergent BioSolutions Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.51 5.32 2.20 0.53 0.10

Emergent BioSolutions Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.45 0.31 0.14 0.10 0.11

Competitive Comparison of Emergent BioSolutions's Cyclically Adjusted PB Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Emergent BioSolutions's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Emergent BioSolutions's Cyclically Adjusted PB Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Emergent BioSolutions's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Emergent BioSolutions's Cyclically Adjusted PB Ratio falls into.



Emergent BioSolutions Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Emergent BioSolutions's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=6.142/37.75
=0.16

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Emergent BioSolutions's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Emergent BioSolutions's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=12.67/131.7762*131.7762
=12.670

Current CPI (Mar. 2024) = 131.7762.

Emergent BioSolutions Quarterly Data

Book Value per Share CPI Adj_Book
201406 13.017 100.560 17.058
201409 13.666 100.428 17.932
201412 14.670 99.070 19.513
201503 14.035 99.621 18.565
201506 14.512 100.684 18.993
201509 15.567 100.392 20.434
201512 16.749 99.792 22.117
201603 16.744 100.470 21.961
201606 16.638 101.688 21.561
201609 13.526 101.861 17.498
201612 14.694 101.863 19.009
201703 14.905 102.862 19.095
201706 15.097 103.349 19.250
201709 16.038 104.136 20.295
201712 18.466 104.011 23.395
201803 17.693 105.290 22.144
201806 18.761 106.317 23.254
201809 19.261 106.507 23.831
201812 19.744 105.998 24.546
201903 19.212 107.251 23.605
201906 19.165 108.070 23.369
201909 20.058 108.329 24.399
201912 21.054 108.420 25.589
202003 20.564 108.902 24.883
202006 22.662 108.767 27.456
202009 23.613 109.815 28.335
202012 27.250 109.897 32.675
202103 28.410 111.754 33.500
202106 28.747 114.631 33.047
202109 28.356 115.734 32.286
202112 31.413 117.630 35.191
202203 31.256 121.301 33.955
202206 30.325 125.017 31.965
202209 29.044 125.227 30.563
202212 27.699 125.222 29.149
202303 23.861 127.348 24.691
202306 18.461 128.729 18.898
202309 13.459 129.860 13.658
202312 12.439 129.419 12.666
202403 12.670 131.776 12.670

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Emergent BioSolutions  (LTS:0IGA) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Emergent BioSolutions Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Emergent BioSolutions's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Emergent BioSolutions (LTS:0IGA) Business Description

Traded in Other Exchanges
Address
400 Professional Drive, Suite 400, Gaithersburg, MD, USA, 20879
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. The company has four main units: vaccines, which produces specialty vaccines for public health threats; devices, such as nasal sprays, skin lotions, and injections; therapeutics, which includes antibody-based treatments; and contract development and manufacturing, which brings treatments to market through collaboration with the pharmaceutical and biotechnology industries and the United States government. Most revenue comes from U.S. government purchases of vaccines, devices, and therapeutic products. The company operates in two reportable segments; the Products Segment and the Services Segment.

Emergent BioSolutions (LTS:0IGA) Headlines

No Headlines